Recombinant human erythropoietin (rHuEPO), a 30-kDa protein therapeutic drug, was approved by the FDA in 1989, and it is being used to treat anemia due to chronic kidney disease or chemotherapy [18]. This evidence concerns the gene EPO and anemia (phenotype).